Global Artemisinin Combination Therapy (ACT) Market Revenue Grows at a CAGR of 8.35%

Introduction

Straits Research released its highly anticipated report, “Global Artemisinin Combination Therapy Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 680.15 million in 2025 and is projected to expand to USD 1394.93 million by 2034, registering a compound annual growth rate (CAGR) of 8.35%.

Market Dynamics

The global artemisinin combination therapy (ACT) market is experiencing strong growth, primarily driven by the increasing prevalence of malaria in tropical and subtropical regions and the widespread adoption of artemisinin-based combination therapies (ACTs) as the standard treatment recommended by the World Health Organization (WHO). Rising government-supported malaria elimination programs, coupled with expanded access to affordable ACTs through public-private partnerships and global health organizations, are further accelerating market expansion.

However, the market faces restraints due to supply chain vulnerabilities and limited cold chain infrastructure in malaria-endemic regions, which affects the timely distribution and stability of ACT formulations. Additionally, fluctuating raw material availability from Artemisia annua cultivation poses challenges to consistent drug supply. On the other hand, several opportunities exist in the development of fixed-dose combinations that enhance treatment compliance, bioavailability, and patient outcomes. Increasing investments in pediatric formulations and collaborations for localized manufacturing in Africa and Asia are also expected to create new growth avenues for the global artemisinin combination therapy market.

Market Highlights

• Type: The artemether + lumefantrine segment held the highest market share in 2025, with a revenue share of 38.23%.
• Distribution Channel: The hospital pharmacies segment dominated the market with a revenue share of 48.52%.
• Regional Insights: North America dominated the market with a 40.17% share, driven by the increasing adoption of advanced malaria treatment protocols and the presence of strong pharmaceutical distribution networks ensuring efficient availability of artemisinin-based therapies.

Competitive Players

1. Sanofi
2. PATH
3. KPC Pharmaceuticals, Inc
4. Guilin Pharmaceutical Co., Ltd
5. Calyx Chemicals and Pharmaceuticals Ltd.
6. Novartis AG
7. Ipca Laboratories Ltd.
8. Cipla Inc.
9. CO, LTD
10. AdvaCare Pharma
11. Ajanta Pharma Ltd.
12. Mylan N.V.
13. Strides Pharma Science Limited
14. Zydus Cadila
15. Ranbaxy Laboratories Limited
16. Bayer AG
17. GSK plc
18. Pfizer Inc
19. Others

Recent Developments

July 2025: Novartis received the Coartem (artemether-lumefantrine) approval by Swissmedic as the first malaria medicine for newborns and young infants.

Segmentation

1. By Type (2026-2034)
   1. Artemether+Lumefantrine
   2. Artesunate+Amodiaquine
   3. Dihydroartemisinin+Piperaquine
   4. Artesunate+Mefloquine
   5. Artesunate+Sulfadoxine-Pyrimethamine
   6. Pyronaridine-Artesunate
   7. Other
2. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Online Pharmacies
   3. Drug Stores & Retail Pharmacies